Free Webinar: Treatment Advances for Peritoneal Mesothelioma
Treatment & Doctors
Written by Sean Marchese, MS, RN | Edited By Walter Pacheco
On Wednesday, June 15, at 8 p.m. EDT, The Mesothelioma Center at Asbestos.com will host a webinar exclusively for peritoneal mesothelioma patients, their families and caregivers. This informative presentation will focus on the latest treatment advances and clinical trials.
Nearly 20% of all mesothelioma cases are the peritoneal type, which occurs in the abdomen. This variant affects the peritoneum, a tissue lining that surrounds and connects sensitive organs throughout the midsection, such as the liver and kidneys.
For years, hyperthermic intraperitoneal chemotherapy, or HIPEC, has been the standard of care for peritoneal patients. However, this aggressive treatment is only available for patients already eligible for mesothelioma surgery. More than 60% of peritoneal patients must look to other treatments for answers.
In this webinar, 15-year peritoneal mesothelioma survivor Tamron Little and I will share the latest research and answer your questions about the newest treatment developments and clinical trials. Tamron has numerous lessons to share about her experiences.
There will be a live Q&A at the end of the presentation where Tamron and I will answer audience questions. We will send a recording via email after the event to anyone who registered.
Who Should Attend the Peritoneal Mesothelioma Treatment Webinar?
Although this webinar focuses on treatment for those with peritoneal mesothelioma, it’s also available to pleural mesothelioma patients.
During the presentation, Tamron will recount her experiences undergoing peritoneal mesothelioma treatment and discuss patients’ struggles finding the right doctor and treatment center. We’ll provide a simple overview of new developments in research and clinical trials currently enrolling across the United States.
You should consider attending if you are:
- A peritoneal mesothelioma patient
- The family or caregiver of a mesothelioma patient
- Interested in new peritoneal mesothelioma treatments and clinical trials
During the live Q&A, Tamron and I will answer audience questions about personal experiences, new treatments, symptoms and clinical trials, and address any concerns viewers might have.
Peritoneal Mesothelioma Treatment Advances
In addition to reviewing the top peritoneal mesothelioma treatment options currently available, we will discuss new approaches for patients who may not be eligible for HIPEC. Many patients wonder whether new treatments such as immunotherapy for mesothelioma will be suitable for them.
Advancements in peritoneal mesothelioma treatment include:
- Using new drug combinations intended as first-line or second-line options
- Expanding current treatments so more patients are eligible
- Adapting successful immunotherapy regimens from pleural mesothelioma treatments
- Applying bio-engineered advances such as nanoparticles and gene therapy
Research studies as recent as April 2022 have identified new treatment methods that are helping patients live longer with fewer symptoms and a lower risk of cancer recurrence. For example, patients who receive repeat HIPEC have a five-year survival rate of 71.8%.
Doctors are also studying the use of immunotherapy for peritoneal mesothelioma patients ineligible for surgery and HIPEC. The combination of Tecentriq and Avastin (generic names atezolizumab and bevacizumab) is a new immunotherapy approach that has improved one-year survival rates to 85%.
Additionally, researchers are finding new genetic biomarkers in DNA that could help identify new types of therapy.
Toward the end of the presentation, the webinar will provide an overview of peritoneal mesothelioma clinical trials currently enrolling in several different states.
Connect Directly with a Peritoneal Mesothelioma Survivor
Webinar co-presenter Tamron Little was diagnosed with peritoneal mesothelioma in 2007 and now works as an activist by raising public awareness about the disease and its causes. She has years of experience helping patients and their families navigate this rare and devastating cancer.
Doctors diagnosed Tamron with peritoneal mesothelioma when she was 21 years old and pregnant with her first child. She would later undergo cytoreductive surgery with HIPEC and intensity-modulated radiation therapy shortly after her son Caleb was born.
She now shares her firsthand experiences with patients and provides a unique perspective on what it’s like to be a mesothelioma survivor. Her stories have been invaluable to peritoneal mesothelioma patients looking for support and inspiration.
